Pulmonary arterial hypertension and rheumatic diseases-from diagnosis to treatment

被引:24
作者
Distler, O. [1 ]
Pignone, A. [2 ]
机构
[1] Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland
[2] Univ Florence, Rheumatol Sect, Dept Med, I-50121 Florence, Italy
关键词
D O I
10.1093/rheumatology/kel314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Survival rates in pulmonary arterial hypertension (PAH) associated with rheumatic diseases, in particular connective tissue diseases such as systemic sclerosis, are even lower than in idiopathic PAH. These low survival rates highlight the need for early diagnosis and treatment in these patients. Transthoracic Doppler-echocardiography is most often used for diagnostic screening of patients at risk. Other screening tests are serum pro-brain-natriuretic peptide (pro-BNP) and diffusion capacity for carbon monoxide (DLCO), which appear to be changed early in the course of the PAH associated with connective tissue diseases. The diagnosis needs to be confirmed by right heart catheterization, which is recommended in all patients with suspected PAH. Besides the conventional background therapy, a number of specific therapies have been evaluated in randomized controlled trials in the recent years. These therapies include prostacyclins and prostacyclin analogues, endothelin-receptor antagonists and phosphodiesterase-5 inhibitors. Response to treatment can be measured by exercise capacity (e.g. 6 min walk distance) and pro-BNP, although certain aspects of validation for these outcome measures are lacking in PAH associated with connective tissue diseases.
引用
收藏
页码:22 / 25
页数:4
相关论文
共 47 条
[1]   N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers [J].
Allanore, Y ;
Borderie, D ;
Meune, C ;
Cabanes, L ;
Weber, S ;
Ekindjian, OG ;
Kahan, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (12) :3503-3508
[2]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[3]  
BARGAGLI E, 2005, RESPIRATION 1209
[4]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[5]   Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].
Barst, Robyn J. ;
Langleben, David ;
Badesch, David ;
Frost, Adaani ;
Lawrence, E. Clinton ;
Shapiro, Shelley ;
Naeije, Robert ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056
[6]  
DISTLER O, 2006, RHEUMATOLOG IN PRESS
[7]   PRIMARY PULMONARY-HYPERTENSION - NATURAL-HISTORY AND THE IMPORTANCE OF THROMBOSIS [J].
FUSTER, V ;
STEELE, PM ;
EDWARDS, WD ;
GERSH, BJ ;
MCGOON, MD ;
FRYE, RL .
CIRCULATION, 1984, 70 (04) :580-587
[8]   Ambrisentan therapy for pulmonary arterial hypertension [J].
Galié, N ;
Badesch, D ;
Oudiz, R ;
Simonneau, G ;
McGoon, MD ;
Keogh, AM ;
Frost, AE ;
Zwicke, D ;
Naeije, R ;
Shapiro, S ;
Olschewski, H ;
Rubin, LJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (03) :529-535
[9]   Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial [J].
Galiè, N ;
Humbert, M ;
Vachiéry, JL ;
Vizza, CD ;
Kneussl, M ;
Manes, A ;
Sitbon, O ;
Torbicki, A ;
Delcroix, M ;
Naeije, R ;
Hoeper, M ;
Chaouat, A ;
Morand, S ;
Besse, B ;
Simonneau, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (09) :1496-1502
[10]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157